Cargando…
Statistical Primer on Biosimilar Clinical Development
A biosimilar is highly similar to a licensed biological product and has no clinically meaningful differences between the biological product and the reference (originator) product in terms of safety, purity, and potency and is approved under specific regulatory approval processes. Because both the or...
Autores principales: | Isakov, Leah, Jin, Bo, Jacobs, Ira Allen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal of Therapeutics
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102275/ https://www.ncbi.nlm.nih.gov/pubmed/26766293 http://dx.doi.org/10.1097/MJT.0000000000000391 |
Ejemplares similares
-
Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis
por: Simoens, Steven, et al.
Publicado: (2017) -
Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence
por: Jacobs, Ira, et al.
Publicado: (2016) -
Clinical considerations for the development of biosimilars in oncology
por: Socinski, Mark A, et al.
Publicado: (2015) -
Gut microbiome health and dysbiosis: A clinical primer
por: Bidell, Monique R., et al.
Publicado: (2022) -
Regulatory considerations in oncologic biosimilar drug development
por: Macdonald, Judith C, et al.
Publicado: (2015)